Oliver is a chartered UK and European Patent Attorney who joined the London Office in September 2020. Oliver has a PhD in Bio-Nanotechnology and a degree in Medical Biochemistry from the University of Leeds. He has a wide range of experience in prosecution, contentious matters, drafting and freedom-to-operate.
Oliver has worked in private practice in IP for four years in both London and Yorkshire with a number of clients ranging from start-ups and universities to multinational companies.
Oliver's main area of focus is nanoscale biotechnology but he has also had experience with technologies such as biologics, medical devices, medical treatments, diagnostic and analytical methods, antibody technology and second medical use inventions for a range of diseases.
Oliver has experience of patent prosecution in the UK and Europe as well as advising clients as to patent prosecution in foreign jurisdictions including the United States, Japan and China.
Medical Biochemistry - University of Leeds
Integrated PhD & MSc – Molecular Scale Engineering – University of Leeds
Thesis entitled “Atomic Force Microscopy of DNA-protein Interactions” – University of Leeds
Post-Graduate Certificate in Intellectual Property - Queen Mary University of London
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.